Phoenix Biotech Acquisition Corp. (CEROW)
OTC PINK OTC PINK Primary Summary
Phoenix Biotech Acquisition Corp. (CEROW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Phoenix Biotech Acquisition Corp. ever had a stock split?
Phoenix Biotech Acquisition Corp. Profile
| Biotechnology Industry | Healthcare Sector | Christopher Ehrlich CEO | OTC PINK Exchange | 71902K113 CUSIP |
| US Country | 8 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CERo Therapeutics Holdings, Inc. is a pioneering immunotherapy company dedicated to the advancement of T cell therapeutics aimed at combating cancer. Established in 2021 and headquartered in South San Francisco, California, the company is at the forefront of developing cutting-edge treatments designed to harness the power of the immune system to fight hematologic malignancies and potentially other cancers. With a robust commitment to scientific innovation and patient care, CERo Therapeutics Holdings, Inc. represents a new wave of hope in the oncology sector.
Products and Services
- CER-1236
As the lead development candidate of CERo Therapeutics Holdings, Inc., CER-1236 is an innovative autologous T cell therapy uniquely engineered for the treatment of various hematologic malignancies. This therapeutic candidate exemplifies the company's focus on leveraging the body's own immune system to attack cancer cells directly. By focusing on autologous therapies—treatments that use the patient's own T cells which are modified and reintroduced into the body—CER-1236 aims to provide a personalized and targeted approach to cancer treatment, promising a new frontier in the fight against these challenging diseases.
